Endocarditis following ocrelizumab in relapsing-remitting MS

Neurol Neuroimmunol Neuroinflamm. 2020 Feb 3;7(3):e680. doi: 10.1212/NXI.0000000000000680. Print 2020 May.

Authors

Simon Faissner¹, Carolin Schwake², Michael Gotzmann², Andreas Mügge², Stephan Schmidt², Ralf Gold²

Affiliations

¹ From the Department of Neurology (S.F., C.S., R.G.) and Department of Cardiology (M.G., A.M.), St. Josef-Hospital, Ruhr-University Bochum, Bochum; and Neurologische Gemeinschaftspraxis (S.S.), Bonn, Germany. simon.faissner@rub.de.
² From the Department of Neurology (S.F., C.S., R.G.) and Department of Cardiology (M.G., A.M.), St. Josef-Hospital, Ruhr-University Bochum, Bochum; and Neurologische Gemeinschaftspraxis (S.S.), Bonn, Germany.

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects*
Endocarditis / chemically induced*
Humans
Immunologic Factors / adverse effects*
Male
Multiple Sclerosis, Relapsing-Remitting / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
ocrelizumab